Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Jasper finds new purpose in merger with Kira while offloading its Tavneos rival (KP-301/KP-402) to Mirador.
Jasper Therapeutics 8-K exhibit describing the Kira acquisition, share issuance, preferred stock private placement, and CVR terms.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Jasper Therapeutics (Nasdaq: JSPR) acquired Kira Pharmaceuticals in an all-stock reverse merger announced July 16, 2026, issuing 5,195,009 common and 4,644,977 non-voting preferred shares and assuming Kira options/SAFEs, making Kira a wholly owned subsidiary focused on complement and immunology. On a fully diluted, as-converted basis, former Kira holders are expected to own ~49.86%, PIPE investors ~43.46%, and pre-transaction Jasper holders ~6.68%. The transaction is paired with a ~$132 million preferred-stock private placement (expected to close July 20, 2026) and a non-transferable contingent value right for pre-close Jasper holders. Concurrently, Kira out-licensed KP-301 and KP-402 to Mirador Therapeutics. A headline financial deal value was not disclosed (all-stock, ownership-percentage structure).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Jasper Therapeutics, Inc. / Kira Pharmaceuticals (this deal) | 2026 | — | — |
| Servier Pharmaceuticals LLC / Day One Biopharmaceuticals Inc. | 2026 | $2.5B | 75 |
| Servier / Edgewise Therapeutics, Inc. | 2026 | $2.6B | 75 |
| AstraZeneca PLC / Dizal Pharmaceutical Co., Ltd | 2026 | $1.5B | 73 |
| Travere Therapeutics, Inc. / Everest Medicines Limited | 2026 | $1.1B | 72 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| Pfizer Inc. / Innovent Biologics, Inc. | 2026 | $10.5B | 71 |
← Browse all deals · How we score deals
More: 2026 deals